Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 08, 2017
Dr Patricia Danzon: Learning From European Health Systems
August 30, 2017
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23, 2017
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
August 16, 2017
Dr Ilene Hollin Outlines Differing Definitions of Value
August 09, 2017
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 03, 2017
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28, 2017
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
July 25, 2017
Dr Steve Pearson on Using Health Technology Assessment to Guide Decision Making
July 23, 2017
Dr Gail Wilensky: Increased Competition a Better Drug Pricing Solution Than Cost Controls
July 16, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Currently Reading
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017

Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform

There are some areas in health policy where Democrats and Republicans can find common ground, like incentivizing greater value, but bipartisan talks won’t happen while there are still active efforts to repeal the Affordable Care Act, said David M. Cutler, PhD, of Harvard University.


There are some areas in health policy where Democrats and Republicans can find common ground, like incentivizing greater value, but bipartisan talks won’t happen while there are still active efforts to repeal the Affordable Care Act (ACA), said David M. Cutler, PhD, of Harvard University.

Transcript (slightly modified)

What areas of the Affordable Care Act do you think can be reformed and improved if Republicans reach across the aisle and work with Democrats?

There’s a lot in the ACA that needs to be addressed and that could be addressed with bipartisan support. The issue about many places in the country where insurers are not entering or leaving is a really big deal that should be addressed. Issues about, are the subsidies adequate for certain types of people or the nature of the policies that people are subsidized for are, again, something where if we had bipartisan support it would be good.

Some of the back-office things, like reinsurance programs and risk adjustment programs for insurers so that they’re not panicked about getting a couple of very unhealthy people are all things that ought to be addressed. And then, things about the organization of the Medicare program, how it goes about paying for things, how it incentivizes greater value in healthcare. All of those are things that, if there were interest, could be done on a very bipartisan basis.

What is the likelihood of bipartisan work being done on reforming the ACA?

Bipartisanship is such a dirty word these days. It won’t happen while there’s ongoing talk of repeal of the ACA, because the Republicans can’t be seen as having a separate set of discussions and Democrats don’t want to feed into discussions that will be used to argue for repeal. I think if repeal looks like it’s going to fail, you may then see some discussions that look like, okay, can we find some things to do that make things work better? There is a lot that could be done there. I think we probably have a little bit more to go before that becomes more of a front-stage issue.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!